Unfortunately, there are no NPM1 inhibitors currentlyused in clinical practice, and a few candidate drugs are in clinicaltrials, such as NucAnt 6L and CIGB-300, but only ATRA is being studiedas an adjuvant for the treatment of AML.52,53 Therefore, the development of new targeted therapy treatments iscritical for the future of patients, to improve the dramatically lowsurvival rate of AML. This evidence concerns the gene NPM1 and acute myeloid leukemia.